• Eloxx Pharmaceuticals appointed a Novartis executive as senior vice president and chief medical officer.
• The appointee’s Novartis responsibilities included U.S. medical affairs leadership for ADPKD product development.
• The new chief medical officer will oversee renal medical strategy across the Alport and ADPKD programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610200931PR_NEWS_USPR_____NE76563) on October 20, 2026, and is solely responsible for the information contained therein.